Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...

Nearly all of Latin America was excluded from the deal, sparking concern the world is missing a critical opportunity to stop ...

A recent phase 3 trial found that twice-yearly injections of Lenacapavir reduce the risk of contracting HIV by 96%. | Drug ...

A new, long-acting injectable to prevent HIV infection could be a “game-changer” in ending the AIDS epidemic, if all who ...

Health experts say lenacapavir could reduce the number of global HIV infections significantly. But it needs to be cheaper to ...

For oral medications that prevent new HIV infection to be effective, the patient must take certain actions, including ...

Lenacapavir, a new twice-yearly injection, offers 96% HIV prevention efficacy, surpassing daily oral PrEP. For oral ...

A new HIV prevention method, a twice-yearly injection of the drug called Lenacapavir, has shown groundbreaking results, ...

Gilead Sciences has announced the outcomes from the Phase III PURPOSE 2 trial evaluating lenacapavir for HIV prevention.

Gilead's new drug, lenacapavir, shows unprecedented success in HIV prevention, offering hope especially for marginalized ...